Vertex Pharmaceuticals Inc NASDAQ:VRTX Price, Chart, News & Insight

Vertex Pharmaceuticals Stock Rises 2.2% After Strong Q2 Results and Higher Revenue Guidance

Vertex Pharmaceuticals (NASDAQ: VRTX) shares rose 2.2% on Tuesday after the biotechnology company reported strong second-quarter results, raised its full-year revenue guidance and highlighted continued progress across both its commercial portfolio and late-stage pipeline.

Second-quarter revenue increased 12% year over year to $3.33 billion, driven by continued strength in its cystic fibrosis (CF) franchise and growing contributions from newer products, including CASGEVY and JOURNAVX. The company also increased its 2026 revenue outlook to $13.1 billion-$13.2 billion from its previous guidance of $12.95 billion-$13.1 billion.

Cystic Fibrosis Business Remains the Growth Engine

Vertex's core CF business continued to deliver solid performance, supported by strong patient demand for ALYFTREK and TRIKAFTA. U.S. revenue increased 11% to $2.06 billion, while international revenue rose 14% to $1.28 billion as ALYFTREK adoption expanded across global markets and CASGEVY infusions continued to grow.

Management expects non-CF products, primarily CASGEVY and the recently launched acute pain treatment JOURNAVX, to generate at least $500 million in revenue during 2026, reflecting the company's ongoing diversification beyond its traditional CF franchise.

Pipeline Expansion and Crinetics Acquisition Strengthen Outlook

Vertex continued advancing its pipeline, with povetacicept remaining on track for a November 30 PDUFA date. The company also announced its planned acquisition of Crinetics Pharmaceuticals, expected to close during the third quarter, adding rare endocrine diseases as a fifth major therapeutic pillar.

CEO Reshma Kewalramani said the company's expanding commercial portfolio and pipeline position Vertex to deliver additional innovative therapies while creating long-term shareholder value.

Strong Balance Sheet Supports Growth Strategy

Vertex ended the quarter with $13.6 billion in cash, cash equivalents and marketable securities, up from $12.3 billion at year-end, supported by strong operating cash flow. The company continued investing in commercial launches and pipeline development while repurchasing shares under its existing buyback program.

What to Watch

Investors will be watching the continued global rollout of ALYFTREK, commercial adoption of CASGEVY and JOURNAVX, the upcoming FDA decision on povetacicept, and the expected completion of the Crinetics acquisition. Markets will also monitor whether Vertex can continue expanding beyond cystic fibrosis while maintaining its strong revenue growth and profitability.

💬

European Investor 08-04-26

Vertex Pharmaceuticals Slips 1% in Pre-Market After Solid Q1 Results

May 5, 2026

Vertex Pharmaceuticals (Nasdaq: VRTX) edged lower by about 1% in Tuesday's pre-market session following the release of its first quarter 2026 earnings report after Monday's close. The modest decline appears to reflect a market that found the results solid but not surprising — a steady, well-managed business delivering in line with expectations rather than a dramatic beat.

Q1 by the Numbers

Total revenue came in at $2.99 billion, an 8% increase compared to the first quarter of 2025. Growth was driven by the continued strength of the company's cystic fibrosis portfolio alongside a meaningful contribution from newer products. In the U.S., revenue rose 7% to $1.78 billion, supported by strong demand for ALYFTREK, higher net prices across CF therapies, and early contributions from CASGEVY and JOURNAVX. Outside the U.S., revenue grew 9% to $1.21 billion, helped in part by favorable foreign exchange movements.

CEO Reshma Kewalramani highlighted that CASGEVY and JOURNAVX together accounted for more than 25% of the company's quarterly growth, calling it a sign of a revenue base that is becoming increasingly diversified beyond cystic fibrosis.

GAAP net income for the quarter was $1.0 billion, up sharply from $646 million in the same period a year ago — though that comparison is flattered by a $379 million intangible asset impairment charge that weighed on Q1 2025 results. Non-GAAP net income came in at $1.1 billion, up $93 million year-over-year. Cash and marketable securities grew to $13.0 billion as of March 31, compared to $12.3 billion at the end of 2025.

Guidance Unchanged

Vertex reiterated its full year 2026 financial guidance without revision, targeting total revenue of $12.95 billion to $13.1 billion. Non-CF product revenue is expected to reach at least $500 million. The company maintained its combined non-GAAP R&D and SG&A expense guidance of $5.65 to $5.75 billion and a non-GAAP effective tax rate of 19.5% to 20.5%.

The unchanged guidance may be one reason the stock is seeing mild selling pressure. In a market that rewards upward revisions, reiterating prior forecasts — even strong ones — can read as a lack of near-term catalysts.

Pipeline Progress

On the pipeline front, Vertex completed a rolling BLA submission for povetacicept, seeking U.S. accelerated approval in IgA nephropathy following positive Phase 3 interim data. The company also initiated a Phase 3 study in primary membranous nephropathy and a Phase 2 study in generalized myasthenia gravis — moves that signal the company is serious about building a fourth franchise in nephrology alongside CF, gene therapy, and pain.

The FDA recently approved label extensions for both ALYFTREK and TRIKAFTA, making approximately 800 more CF patients in the U.S. eligible for treatment for the first time. Additionally, Vertex submitted for U.S. approval of CASGEVY in children ages 5 to 11 with sickle cell disease or transfusion-dependent beta thalassemia, receiving a Commissioner's National Priority Voucher indicating an accelerated review timeline.

JOURNAVX, the company's first-in-class non-opioid pain medication launched in March 2025, surpassed one million total prescriptions filled, with more than 350,000 filled in Q1 alone. Vertex recorded $29 million in JOURNAVX revenue for the quarter and recently secured Medicare Part D coverage adding approximately 10 million lives.

The Bigger Picture

Vertex is not a company in crisis — far from it. It has a dominant position in cystic fibrosis, a growing gene therapy business, and a pain franchise gaining meaningful traction. The mild pre-market dip likely reflects the absence of a positive guidance revision rather than any fundamental concern. For long-term investors, the pipeline news — particularly around povetacicept in nephrology — may prove to be the most significant takeaway from the quarter.

💬

The Investor 05-05-26

Vertex to Announce First Quarter 2026 Financial Results on May 4th

💬

Global Finance News 04-07-26

Vertex Pharmaceuticals reported new Phase 4 study data showing its non-opioid pain drug JOURNAVX enabled opioid-free recovery in most patients following aesthetic and reconstructive surgeries.

In the study of 99 patients, 90.9% remained opioid-free for up to 14 days after surgery when JOURNAVX was used as part of multimodal pain treatment with medicines such as acetaminophen and ibuprofen. About 90.7% of patients rated the treatment’s effectiveness as excellent, very good, or good.

The company said the results highlight the drug’s potential to support opioid-free pain management after surgery. The findings will be presented at the American Academy of Pain Medicine’s PainConnect 2026 meeting.

Business Wire

💬

Global Finance News 03-06-26

Vertex Pharmaceuticals reported strong fourth quarter and full-year 2025 results, supported by growth in its cystic fibrosis (CF) franchise and contributions from newer products.

In Q4 2025, total revenue rose 10% year over year to $3.19 billion. U.S. revenue increased 12% to $2.06 billion, driven by strong CF demand, including ALYFTREK, and contributions from CASGEVY and JOURNAVX. International revenue grew 5% to $1.13 billion. GAAP net income was $1.2 billion, up from $913 million in Q4 2024.

For full-year 2025, revenue increased 9% to $12.0 billion, with U.S. revenue up 13% to $7.55 billion and international revenue up 3% to $4.45 billion. GAAP net income reached $4.0 billion, compared to a net loss in 2024, reflecting higher product revenue and the absence of large Alpine acquisition-related charges from the prior year. Vertex ended 2025 with $12.3 billion in cash and marketable securities.

For 2026, the company expects total revenue of $12.95–$13.1 billion, including at least $500 million from non-CF products such as CASGEVY and JOURNAVX. Vertex also remains on track to complete a BLA filing for U.S. accelerated approval of povetacicept in IgA nephropathy in the first half of 2026.

Business Wire

💬

WS Investor 02-13-26

Vertex Unveils First CASGEVY Data in Children 5–11 and Plans Global Regulatory Filings for 2026

Vertex presented the first clinical data showing that CASGEVY, its CRISPR-based gene-editing therapy, produced strong and durable benefits in children ages 5–11 with severe sickle cell disease or transfusion-dependent beta thalassemia. All evaluable young patients met key endpoints: sickle cell patients remained free of vaso-occlusive crises for at least 12 months, and thalassemia patients achieved transfusion independence. Safety findings were consistent with expectations from myeloablative conditioning and transplant. Longer-term results in patients 12 and older continued to show sustained remission and transfusion independence. Vertex plans to begin global regulatory submissions for the 5–11 age group in the first half of 2026.

💬

Global Finance News 12-07-25

Vertex delivers 11% revenue growth in Q3, raises 2025 revenue outlook to up to $12 billion

Vertex Pharmaceuticals (Nasdaq: VRTX) reported third-quarter 2025 revenue of $3.08 billion, up 11% year over year, driven by continued strength in cystic fibrosis (CF) therapies, including ALYFTREK, and early sales from new launches CASGEVY and JOURNAVX. U.S. revenue grew 15% to $1.98 billion, while international revenue rose 4% to $1.10 billion. GAAP net income reached $1.1 billion, and non-GAAP net income was $1.2 billion, reflecting strong product demand and disciplined expense management.

The company refined its full-year 2025 guidance, now expecting total revenue of $11.9–$12.0 billion and combined non-GAAP R&D, AIPR&D, and SG&A expenses of $5.0–$5.1 billion. Vertex also lowered its non-GAAP effective tax rate forecast to 17–18% due to one-time R&D tax benefits.

CEO Dr. Reshma Kewalramani highlighted progress in the R&D pipeline, including five programs in pivotal development, full enrollment in the Phase 3 IgAN trial for povetacicept, and plans to submit the first module of its Biologics License Application to the FDA by year-end. Vertex ended the quarter with $12 billion in cash and marketable securities, up from $11.2 billion at the end of 2024.

💬

The Investor 11-04-25

Vertex Highlights New Data on Cystic Fibrosis Treatments at NACFC 2025

Vertex Pharmaceuticals (Nasdaq: VRTX) presented new clinical data at the North American Cystic Fibrosis Conference (NACFC) in Seattle, showcasing the benefits of its CFTR modulators, including the latest therapy ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor).

The studies show that reductions in sweat chloride (SwCl) — a marker of improved CFTR function — correlate with better outcomes in cystic fibrosis (CF) patients, particularly children. In Phase 3 trials, ALYFTREK achieved greater sweat chloride reduction than TRIKAFTA, suggesting stronger potential improvements in lung function and quality of life.

Post-hoc analyses found fewer pulmonary exacerbations and hospitalizations for patients treated with ALYFTREK compared to TRIKAFTA. Data also confirmed that starting modulator therapy earlier in childhood yields broader clinical benefits, including better lung health and nutrition.

💬

The Investor 10-23-25

Vertex Pharmaceuticals announced major progress in its kidney disease pipeline, including FDA Breakthrough Therapy Designation for povetacicept in IgA nephropathy with potential U.S. accelerated approval in H1 2026, completion of enrollment for the interim cohort of the Phase 2/3 AMPLITUDE trial of inaxaplin in APOL1-mediated kidney disease (also targeting accelerated approval), and initiation of a Phase 2 proof-of-concept study for VX-407 in autosomal dominant polycystic kidney disease, underscoring its push to deliver first-in-class therapies for serious kidney conditions.

💬

The Investor 09-25-25

Vertex Pharmaceuticals has partnered with basketball world champion Jayson Tatum to raise awareness of JOURNAVX, its newly approved non-opioid medicine for moderate-to-severe acute pain. After rupturing his Achilles tendon during the 2025 playoffs, Tatum turned to JOURNAVX as an alternative to opioids, citing its effectiveness in managing his post-surgical pain without the side effects he experienced from traditional treatments. The FDA approved JOURNAVX in January 2025, making it the first new class of acute pain medicine in over two decades. By sharing his recovery story, Tatum hopes to encourage others to explore non-opioid options, while Vertex underscores its commitment to offering safer alternatives in pain management.

💬

The Investor 09-23-25

NASDAQ:VRTXFollow

NASDAQ:VRTX